NCT06727227Recruiting
Real-world Study of Trastuzumab Deruxtecan in Patients With Unresectable or Metastatic HER2-low Breast Cancer
REal-world Study of Trastuzumab deruXtecan in Patients With unresectabLe or Metastatic Breast Cancer Expressing HER2-lOw From BulgaRia and SlovEnia (EXPLORE)
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
A longitudinal, non-interventional study with trastuzumab deruxtecan for patients with HER2-low expressing unresectable or metastatic breast cancer in Bulgaria and Slovenia
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 138 (estimated)
- First submitted
- 20 Nov 2024
- Start date
- 29 Jan 2025
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06727227
What you commit to
- Study type: Observational
- Planned participants: 138
- From 29 Jan 2025 to the primary completion date, 31 Oct 2027
- 8 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of other primary malignancies in 2 years prior to unresectable or mBC diagnosis.
- HER2-low status patients who have previously documented HER2+ status in the same tumor.
Other
- Pregnancy or breastfeeding.
- Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded.
Who the study is looking for
- Adult patient (age ≥18 years) with histological or cytological confirmed diagnosis of unresectable or mBC.
- Documented HER2-low status (IHC1+, IHC2+/ISH-) in patients who have received prior chemotherapy in the metastatic setting or documented HER2-low status (IHC 1+, IHC 2+/ISH-) in patients who have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
- Recent prior decision to initiate therapy of T-DXd per SmPC (up to 30 days). Documentation confirming this decision will be required and collected.
- Able and willing to provide informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Burgas | Bulgaria | Recruiting |
| - Coordinator of this site? Confirm its status | Panagyurishte | Bulgaria | Not yet recruiting |
| - Coordinator of this site? Confirm its status | Plovdiv | Bulgaria | Not yet recruiting |
| - Coordinator of this site? Confirm its status | Sofia | Bulgaria | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Stara Zagora | Bulgaria | Not yet recruiting |
| - Coordinator of this site? Confirm its status | Varna | Bulgaria | Active, not recruiting |
| - Coordinator of this site? Confirm its status | Ljubljana | Slovenia | Recruiting |
| - Coordinator of this site? Confirm its status | Maribor | Slovenia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.